T2DM (Type 2 Diabetes Mellitus) Clinical Trial
Official title:
A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
Verified date | October 2022 |
Source | Daewoong Pharmaceutical Co. LTD. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
Status | Completed |
Enrollment | 140 |
Est. completion date | November 25, 2021 |
Est. primary completion date | November 25, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Adults aged 19 to 80 years 2. Subjects with 7% = HbA1c = 10% who have been diagnosed with T2DM at least 8 weeks 3. Subjects with BMI of 20-45 kg/m2 4. Subjects who have been on a stable diet and exercise program for at least 8 weeks 5. Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study Exclusion Criteria: 1. Different type of diabetes mellitus which is not T2DM (type 1 diabetes mellitus, secondary diabetes mellitus, or congenital renal glucosuria) 2. Symptoms of stress urinary incontinence, dysuria that is not controlled by medications due to neurogenic bladder or prostatic hyperplasia, anuria, oliguria, or urinary retention 3. Severe diabetes complications (proliferative diabetic retinopathy, nephropathy of stage 4 or higher, or serious diabetic neuropathy) 4. eGFR < 60 mL/min/1.73 m2 5. Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding, active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is not controlled by medication, etc. 6. Uncontrolled hypertension (SBP >180 mmHg or DBP > 110 mmHg) |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Daewoong pharmatceutical | Seoul |
Lead Sponsor | Collaborator |
---|---|
Daewoong Pharmaceutical Co. LTD. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HbA1c level at Week 24 after administration of the IP | 1.Change from Visit 2 (randomization) in HbA1c level at Week 24 after administration of the IP | at Week 24 | |
Secondary | HbA1c level at Weeks 6, 12, and 18 after administration of the IP | 1.Changes from Visit 2 (randomization) in HbA1c level at Weeks 6, 12, and 18 after administration of the IP | at weeks 6, 12, and 18 | |
Secondary | FPG level at Weeks 6, 12, 18, and 24 after administration of the IP | 2.Changes from Visit 2 (randomization) in FPG level at Weeks 6, 12, 18, and 24 after administration of the IP | at weeks 6, 12, 18, and 24 | |
Secondary | HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP | 3.Proportions of subjects who achieved HbA1c level < 7% at Weeks 6, 12, 18, and 24 after administration of the IP | at weeks 6, 12, 18, and 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01373814 -
Nutritional Therapy for Diabetic Cardiomyopathy
|
||
Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
Completed |
NCT05376930 -
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
|
Phase 3 | |
Recruiting |
NCT04682795 -
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
|
N/A | |
Recruiting |
NCT06350890 -
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04634500 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
Phase 3 | |
Recruiting |
NCT03789695 -
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
|
Phase 4 | |
Completed |
NCT04688359 -
Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM
|
N/A | |
Completed |
NCT05983289 -
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
Completed |
NCT03467932 -
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT05376969 -
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
|
Phase 3 | |
Recruiting |
NCT06415773 -
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
|
Phase 3 | |
Recruiting |
NCT06094491 -
Virtual Diabetes Group Visits Across Health Systems
|
Phase 2 | |
Completed |
NCT05279911 -
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
|
N/A | |
Active, not recruiting |
NCT03257449 -
Effect of Viscous Soluble Fibres on Body Weight
|
N/A | |
Terminated |
NCT04754334 -
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
|
Phase 3 | |
Not yet recruiting |
NCT06293417 -
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
|
||
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A |